Q.01

What are the veterinary medicines regulations in the UK?

In the UK, veterinary medicines are governed mainly by the Veterinary Medicines Regulations 2013 (SI 2013/2033, the VMR). The VMR came into force on 1 October 2013 [1]. In Great Britain the text now carries the changes made by the Veterinary Medicines (Amendment etc.) Regulations 2024 (SI 2024/567), in force from 17 May 2024 [2]. Northern Ireland follows a separate track under the Windsor Framework, with EU veterinary medicine rules taking effect there from 1 January 2026 (VMD news, 31 Oct 2025). The Veterinary Medicines Directorate (VMD) administers the system (VMD guidance).

Approach: I read the current revised text of the VMR 2013 and VMD guidance on GOV.UK, and opened the VMD's official Northern Ireland pages.

Core rules in the VMR 2013 (GB text unless stated)

TopicRule
Scope (reg. 2)A "veterinary medicinal product" is a substance presented as treating or preventing disease in animals, or used to restore, correct or modify physiological functions or to make a diagnosis. The 2024 amendment added substances used for euthanasia [2].
Exclusions (reg. 3)The VMR does not apply to products based on radioactive isotopes. It also does not apply to products used in procedures licensed under the Animals (Scientific Procedures) Act 1986, with conditions where the animals enter the food chain [3].
Placing on the market (reg. 4, Schedules 1, 1A, 1B)No person may place a product on the market unless the Secretary of State has granted a marketing authorisation (MA), or for Schedule 1B products issued a QNIG certificate. Schedule 1A covers converted EU MAs [4].
Schedule 1 contentApplications, generic/hybrid/bibliographic routes, parallel imports, labelling and package leaflets, pharmacovigilance (QPPV, signal management) and homeopathic registration [5]
Off-MA supply (reg. 6)The MA holder is guilty of an offence if a product "not completely in accordance with" the MA is supplied [6].
Manufacture (reg. 5, Schedule 2)Every stage of manufacture must be done by the manufacturer named in the MA. Schedule 2 covers manufacturing authorisations, GMP, qualified persons, autogenous vaccines, blood banks, stem cells and active substance registration [7][8].
Supply and possession (reg. 7)No person may supply a product past its expiry date, or supply an authorised human medicine for an animal except via a vet or a vet's written prescription [9].
Administration (reg. 8)Only products with a UK MA, used within its terms, may be administered, unless Schedule 4 (cascade) or Schedule 6 (small pet animal exemption) applies [10].
Wholesale (reg. 13, Schedule 3 Part 2)A wholesale dealer's authorisation is required [11].
Antibiotic data (reg. 24A, new in 2024)On written notice, MA, manufacturing and wholesale holders, food-animal keepers, feed manufacturers and vets must provide antibiotic sales and usage data [12].
Other schedulesSchedule 5: medicated feedingstuffs and specified feed additives. Schedule 6: small pet animal exemptions. Schedule 7: fees [13][14][15]

Distribution categories (Schedule 3, para 1)

There are four categories: POM-V, POM-VPS, NFA-VPS and AVM-GSL.

  • Must be POM-V: narcotic or psychotropic products, and products needing a vet's diagnosis. In GB the 2024 amendment added antimicrobials, euthanasia products, hormonal or thyrostatic products and beta-agonists.
  • Must be POM-V or POM-VPS: products for food-producing animals (unless all the criteria in para 1(6) are met), and new active substances. In GB, immunologicals were added in 2024.

[16]

The cascade (Schedule 4)

If no UK-authorised product exists for a condition, the vet may use the following, in this order:

  1. a UK veterinary product authorised for another species or condition;
  2. a UK human medicine, or a veterinary product authorised in another country (an import certificate is needed);
  3. an extemporaneous preparation.

For food-producing animals, all substances must have a maximum residue limit set under Regulation (EC) No 470/2009, or fall outside its scope. Minimum withdrawal periods also apply, for example 28 days for meat and offal where the product is not authorised for food-producing animals [17].

Penalties (reg. 44)

JurisdictionSummary convictionConviction on indictment
England and WalesFine up to the statutory maximum and/or up to 6 months' imprisonmentFine and/or up to 2 years
ScotlandFine up to the statutory maximum and/or up to 12 months' imprisonmentFine and/or up to 2 years

Directors and partners can also be liable [18].

Northern Ireland

  • Separate text: The VMR keeps separate NI versions of many provisions. In those versions an MA may come from the Secretary of State or the European Medicines Agency, and the NI departments take over certain enforcement powers [4][19].
  • Authorisation routes: The VMD says NI applications follow "the requirements set out within the EU Regulation". Routes are a national NI MA (only if the product is not already authorised in EU member states) or the EU centralised, mutual recognition or decentralised procedures. A GB MA covers England, Wales and Scotland only (VMD).
  • End of the grace period: It ended on 31 December 2025, and EU veterinary medicine requirements came into effect in NI on 1 January 2026. Two schemes support supply: the Veterinary Medicines Internal Market Scheme and the Veterinary Medicines Health Situation Scheme (VMD news; VMD information hub). The official pages I opened don't name the specific EU regulation that applies in NI or give end dates for the two schemes.
  • NI to GB (unfettered access): NI-based MA holders of qualifying products can place them on the GB market under "unfettered access". They must meet transparency arrangements, giving the VMD the same data they give the EU regulator. The VMD then issues a certificate within 30 days [20].

I can go deeper on any part, for example the MA dossier rules in Schedule 1, the SQP and retail supply rules, or medicated feed under Schedule 5.

Q.02

How do EU veterinary medicine approvals work?

In the EU, a veterinary medicine can only be placed on the market once it holds a marketing authorisation (MA). The MA is granted either by a national competent authority or, for the centralised route, by the European Commission. This is set out in Regulation (EU) 2019/6, which has applied since 28 January 2022 and repealed Directive 2001/82/EC [21][22]. An MA is valid for an unlimited period, and it "shall only be granted to an applicant established in the Union". The holder must stay established in the EU too [23].

Approach: I read the consolidated text of Regulation (EU) 2019/6 (the version dated 28 January 2022) as published on EUR-Lex. I did not go through the implementing and delegated acts made under it, such as the list of variations that need no assessment.

The five routes (Art. 5(1), 6)

Applications go to the European Medicines Agency (EMA) for the centralised route and to national competent authorities for every other route. All applications must be submitted electronically [24].

RouteScopeKey timelines
Centralised (Arts 42-45)Mandatory for: biotech products (recombinant DNA, controlled gene expression, hybridoma/monoclonal antibodies); performance enhancers; active substances not yet authorised in the EU as a veterinary medicine; engineered allogeneic tissue/cell products; and novel therapies. Optional for any other product with no existing EU MA. The MA is valid throughout the EU. [25]EMA opinion within 210 days, extendable by up to 90. Accelerated assessment cuts this to 150 days for products of major interest. The applicant may request re-examination within 15 days. The Commission prepares a draft decision within 15 days of the opinion and then adopts the decision by implementing act. [26][27]
National (Arts 46-47)One Member State only. Not available for products under Art. 42(2), or where a national MA has been granted or an application is pending in another Member State. [28]Maximum 210 days [29]
Decentralised (DCP) (Arts 48-49)Several Member States at once, with no prior national MA. A reference Member State (RMS) leads. [30]The RMS issues its assessment report within 120 days. The concerned Member States (CMS) have 90 days to object, and only on the ground of a potential serious risk to human or animal health or to the environment. If there is agreement, national MAs follow within 30 days of agreement plus translations. [31]
Mutual recognition (MRP) (Arts 51-52)Extends an existing national MA. At least six months must pass after the national MA is granted.Updated RMS report within 90 days. CMS have 90 days to object. MAs follow within 30 days. [32]
Subsequent recognition (Art. 53)Adds further Member States after a DCP or MRP is finished. The application must also include the list of national decisions, the variations made since grant and a pharmacovigilance summary.The RMS forwards an updated report within 60 days. Each new Member State grants within 60 days. [33]

Disagreements (Art. 54): Objections are referred to the coordination group, which has 90 days to seek agreement. If no consensus is reached, the case goes to the Commission, which prepares a draft decision within 30 days and then decides by implementing act [34].

The dossier (Art. 8)

Every application must contain:

  • the Annex I information;
  • technical documentation on quality, safety and efficacy, as set out in Annex II;
  • a summary of the pharmacovigilance system master file.

Some products need more:

  • Antimicrobials: data on risks to public or animal health or the environment, and measures to limit antimicrobial resistance.
  • Food-producing species: where a substance is not yet allowed under Regulation (EC) No 470/2009, proof that a valid maximum residue limit (MRL) application has been made to the EMA.
  • GMO-containing products: the documents required under Directive 2001/18/EC.
  • National route: a declaration that no application has been made, and no MA granted, in another Member State or in the Union.

[35]

For food-producing species, an MA can only be granted if the active substance is allowed under Regulation 470/2009 [23].

Abridged and special applications

TypeWhat it removes or requires
Generic (Art. 18)No safety or efficacy data is needed if bioequivalence is shown (or its absence justified) and the reference product's data protection has expired or will expire within two years [36]
Hybrid (Art. 19)Pre-clinical or clinical data is required where the product differs from the reference (active substance, indication, strength, form or route), where bioequivalence cannot be shown, or where a biological differs in raw materials or process [37]
Combination (Art. 20)No safety or efficacy data is needed for each individual known active substance [38]
Informed consent (Art. 21)No quality, safety or efficacy data is needed if the applicant holds a letter of access [39]
Bibliographic (Art. 22)The active substance must have been in well-established veterinary use in the EU for at least 10 years [40]
Limited market (Arts 23-24)Reduced safety or efficacy data is allowed if benefit outweighs risk. The MA is valid for 5 years and can be renewed for further 5-year periods. The re-examination application is due at least 6 months before expiry [41][42]
Exceptional circumstances (Arts 25-27)Incomplete quality, safety or efficacy data is allowed where there is an animal or public health need. Conditions or post-authorisation studies may be imposed. The MA is valid for 1 year, with re-examination due at least 3 months before expiry [43][44][45]
Homeopathic registration (Art. 86)Applies where the product uses a route described in a pharmacopoeia, contains no more than 1 part per 10,000 of the mother tincture, and has no therapeutic indication [46]

Outcome, classification and refusal

  • Outcome (Art. 33): A favourable assessment produces the summary of product characteristics (SPC), the supply conditions including legal classification, and the labelling and package leaflet texts [47].

  • Prescription status (Art. 34): These products must be classified as subject to veterinary prescription:

    • narcotic or psychotropic products;
    • products for food-producing animals;
    • antimicrobials;
    • products needing a precise prior diagnosis;
    • euthanasia products;
    • active substances authorised in the EU for less than 5 years;
    • immunologicals;
    • hormonal, thyrostatic or beta-agonist products.

    Some of these categories can still be exempted if all the criteria in Art. 34(3) are met. The exemption is not available for narcotics, antimicrobials, euthanasia products or hormonal products [48].

  • Refusal (Art. 37): Grounds include:

    • a negative benefit-risk balance;
    • an antimicrobial presented as a growth or yield promoter;
    • an insufficient withdrawal period;
    • an antimicrobial or antiparasitic resistance risk that outweighs the benefit;
    • a PBT or vPvB active substance in a product for food-producing animals, unless it is essential.

    An antimicrobial shall be refused if it is reserved for human use [49].

Data protection (Arts 38-40)

ProductsProtection period
Cattle, meat sheep, pigs, chickens, dogs and cats10 years
Antimicrobials for those species, with an active substance new to the EU14 years
Other species14 years
Bees18 years

Protection can be extended by 1 year per additional major species, or by 4 years for other species. The total "shall not exceed 18 years". New MRL data gets 5 years of protection. Variations that reduce resistance or improve the benefit-risk balance get 4 years [50][51]. Reference products authorised before 28 January 2022 keep the old Directive's protection periods [52].

After authorisation: variations (Arts 60-67)

  • No assessment needed: Variations on the Commission's list are recorded by the MA holder in the Union product database within 30 days of implementation [53].
  • Assessment needed: All other variations need an application [54]. The assessment is done within 60 days, extendable to 90 [55]. The MA is then amended within 30 days of the procedure ending and translations being received [56].

Transition from the old regime (Art. 152)

MAs granted under Directive 2001/82/EC or Regulation (EC) No 726/2004 before 28 January 2022 are deemed granted under Regulation 2019/6. Products placed on the market under the old rules may continue to be made available until 29 January 2027, even if they do not comply with the new Regulation [52].

From your earlier question: a UK company cannot hold an EU MA itself, because of the EU establishment requirement in Art. 5(4). I can go into the Annex II dossier requirements, the MRL step under Regulation 470/2009, or the implementing act listing variations that need no assessment.

Q.03